Inhibition of drug-induced DNA fragmentation, but not cell death, of glioma cells by non-caspase protease inhibitors

被引:18
作者
Eitel, K [1 ]
Wagenknecht, B [1 ]
Weller, M [1 ]
机构
[1] Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany
关键词
glioma; protease inhibitors; chemotherapy; DNA fragmentation;
D O I
10.1016/S0304-3835(99)00076-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The role of non-caspase protease activation in drug-induced cell death of glioma cells was examined. Neither calpain inhibitors I or II, phenylmethylsulfonyl fluoride (PMSF), N-alpha -p-tosyl-L-lysine chloromethyl ketone (TLCK), N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), E64, leupeptin nor pepstatin inhibit the cytotoxicity of vincristine, cisplatin, doxorubicin, cytarabine, camptothecin, BCNU or VM26 in two malignant glioma cell lines, T98G and LN-229. However, DNA fragmentation induced by VM26 is inhibited by calpain inhibitor I, PMSF, TLCK and TPCK, and that induced by camptothecin by calpain inhibitors I and II and TPCK. Moreover, protease inhibitors fail to abrogate CD95 ligand-induced apoptosis even though DNA fragmentation is attenuated by calpain inhibitor II and TPCK. Thus, non-caspase protease activation is not required for drug-induced apoptosis of glioma cells. Protease inhibitor-mediated inhibition of DNA fragmentation operates downstream of the commitment point for cell death. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:11 / 16
页数:6
相关论文
共 14 条
[1]  
BRUNO S, 1992, LEUKEMIA, V6, P1113
[2]   Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells [J].
Friesen, C ;
Herr, I ;
Krammer, PH ;
Debatin, KM .
NATURE MEDICINE, 1996, 2 (05) :574-577
[3]   Protease inhibitors block apoptosis at intermediate stages: A compared analysis of DNA fragmentation and apoptotic nuclear morphology [J].
Ghibelli, L ;
Maresca, V ;
Coppola, S ;
Gualandi, G .
FEBS LETTERS, 1995, 377 (01) :9-14
[4]  
KAUFMANN SH, 1993, CANCER RES, V53, P3976
[5]   Differential suppression by protease inhibitors and cytokines of apoptosis induced by wild-type p53 and cytotoxic agents [J].
Lotem, J ;
Sachs, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (22) :12507-12512
[6]   Serine protease inhibitors block neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin [J].
Mansat, V ;
Bettaieb, A ;
Levade, T ;
Laurent, G ;
Jaffrezou, JP .
FASEB JOURNAL, 1997, 11 (08) :695-702
[7]   Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53 [J].
Muller, M ;
Strand, S ;
Hug, H ;
Heinemann, EM ;
Walczak, H ;
Hofmann, WJ ;
Stremmel, W ;
Krammer, PH ;
Galle, PR .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (03) :403-413
[8]   The role of proteases during apoptosis [J].
Patel, T ;
Gores, GJ ;
Kaufmann, SH .
FASEB JOURNAL, 1996, 10 (05) :587-597
[9]   Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases [J].
Shimizu, T ;
Pommier, Y .
LEUKEMIA, 1997, 11 (08) :1238-1244
[10]   Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing [J].
Wagenknecht, B ;
Schulz, JB ;
Gulbins, E ;
Weller, M .
CELL DEATH AND DIFFERENTIATION, 1998, 5 (10) :894-900